As to ibrutinib, a BTK inhibitor, in a phase II study of 80 R/R DLBCL, only 37% ABC and 5% GCB subtypes were responsive and the response rate of all DLBCL tumors was 19% [17]. Here, BTK is linked to diffuse large B-cell lymphoma.